Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection

FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):33-42. doi: 10.1111/j.1574-695X.2003.tb00646.x.

Abstract

Here we describe a lethal mouse model infected with dengue virus type 2 with several similarities to human DEN-2 infection. Clinically animals demonstrated anemia, thrombocytopenia, pre-terminal paralysis and shock. The most impressive changes were seen with tumor necrosis factor (TNF)-alpha, which abruptly and steeply increased 24 h before the exitus (mean at day 6). Serum levels of IL-1beta, IL-6, IL-10, IL-1 receptor antagonist and soluble TNF receptor I continuously increased during the time of infection. A 100% mortality rate was noted in that group of animals. Treating animals with anti-TNF-alpha serum reduced mortality rate down to 40% (P<0.05). Our model supports the view that activation of innate immune response is at least partially responsible for mortality in DEN-2 infection, and in line with this concept, anti-TNF treatment significantly reduces mortality rates.

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Antibodies, Viral / therapeutic use*
  • Dengue / mortality
  • Dengue / physiopathology
  • Dengue / therapy*
  • Dengue Virus / immunology
  • Dengue Virus / pathogenicity
  • Disease Models, Animal*
  • Humans
  • Immunization, Passive
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Antibodies, Viral
  • Tumor Necrosis Factor-alpha